A proteomic signature for dementia with Lewy bodies

We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD).

• Publication year

  2019

• Venue

  Alzheimer's & Dementia

• Publication date

  2019-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.dadm.2019.01.006PMID 30923734PMCID 6424013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome

  2020cited by this paper
• Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study

  2019cited by this paper
• Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

  2018cited by this paper
• Amyloid-β Plaques in Clinical Alzheimer’s Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity

  2018cited by this paper
• High performance plasma amyloid-beta biomarkers for Alzheimer's disease

  2018cited by this paper
• Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB consortium

  2018cited by this paper
• High performance plasma amyloid-β biomarkers for Alzheimer’s disease

  2018cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2017cited by this paper
• Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

  2017cited by this paper
• PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.

  2016cited by this paper
• Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics.

  2016cited by this paper
• A blood screening test for Alzheimer's disease

  2016cited by this paper
• Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research

  2015cited by this paper
• MDS clinical diagnostic criteria for Parkinson's disease

  2015cited by this paper
• Molecular Markers of Amnestic Mild Cognitive Impairment among Mexican Americans

  2015cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues

  2014cited by this paper
• The future of blood‐based biomarkers for Alzheimer's disease

  2014cited by this paper
• MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies

  2013cited by this paper
• Biomarkers of Alzheimer's Disease Among Mexican Americans

  2013cited by this paper
• The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines

  2012cited by this paper
• Biomarkers in Parkinson's disease: an update.

  2012cited by this paper
• Multimodality imaging characteristics of dementia with Lewy bodies.

  2012cited by this paper
• Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies.

  2012cited by this paper
• Biomarkers in dementia with Lewy bodies: a review

  2012cited by this paper
• A Blood-Based Algorithm for the Detection of Alzheimer’s Disease

  2011cited by this paper
• α-Synuclein in Parkinson disease and other neurodegenerative disorders

  2011cited by this paper
• Biomarkers of Parkinson's disease and Dementia with Lewy bodies.

  2011cited by this paper
• Neuropathology underlying clinical variability in patients with synucleinopathies

  2011cited by this paper
• Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders

  2011cited by this paper
• A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI

  2011cited by this paper
• Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies

  2011cited by this paper
• A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.

  2010cited by this paper
• A serum protein-based algorithm for the detection of Alzheimer disease.

  2010cited by this paper
• Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

  2010cited by this paper
• Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease

  2010cited by this paper
• CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

  2010cited by this paper
• Comparison of Conventional ELISA with Electrochemiluminescence Technology for Detection of Amyloid-β in Plasma

  2010cited by this paper
• Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum

  2009cited by this paper
• A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies

  2008cited by this paper
• Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed Cases

  2008cited by this paper
• Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

  2007cited by this paper
• The Role of Biomarkers in Clinical Trials for Alzheimer Disease

  2006cited by this paper
• Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank

  2002cited by this paper
• Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies.

  2000cited by this paper
• Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease.

  1999cited by this paper
• Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease'

  1998cited by this paper
• The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association

  1997cited by this paper
• Operational criteria for senile dementia of Lewy body type (SDLT)

  1992influential reference
• Presenile dementia with Alzheimer-, Pick- and Lewy-body changes

  1976cited by this paper

• Alzheimer's disease plasma biomarkers and physical functioning in a diverse sample of adults

  2025cites this paper
• Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings.

  2025cites this paper
• Attitudes and Preferences Towards Screening for Dementia From the Perspectives of Healthcare Professionals: An Updated Systematic Review

  2025cites this paper
• Precision Medicine for Preventing Alzheimer’s Disease: Analysis of the ADAPT Study

  2023cites this paper
• CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease

  2023cites this paper
• CSF proteome profiling reveals highly specific biomarkers for dementia with Lewy bodies.

  2023cites this paper
• Evaluation of Associations of Growth Differentiation Factor-11, Growth Differentiation Factor-8 and their Binding Proteins Follistatin and Follistatin-like protein-3 with Dementia and Cognition.

  2023cites this paper
• Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies.

  2023cites this paper
• A Blood Screening Test for Dementia with Lewy Bodies for Primary Care

  2023cites this paper
• Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer’s Disease in the HABS-HD Study

  2023cites this paper
• Plasma Biomarkers of Alzheimer's Disease Are Associated with Physical Functioning Outcomes Among Cognitively Normal Adults in the Multi-Ethnic HABS-HD Cohort.

  2022cites this paper
• Proteomic and metabolomic biomarkers of Alzheimer's disease: Opportunities to advance precision medicine and clinical trials

  2022cites this paper
• Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study

  2022cites this paper
• Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview.

  2022cites this paper
• What we have learned to date from the omics approach to non-Alzheimer's dementias.

  2022cites this paper
• "The Use of Proteomics in Dementia with Lewy Bodies"/ "From Protein Biomarkers to Proteomics in Dementia with Lewy Bodies".

  2022cites this paper
• Parkinson’s Disease Blood Test for Primary Care

  2022influential citation
• Clinical characteristics of Lewy body dementia in Chinese memory clinics

  2021cites this paper
• Recursive Support Vector Machine Biomarker Selection for Alzheimer’s Disease

  2021cites this paper
• A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community‐dwelling Mexican Americans and non‐Hispanic Whites: A method for increasing representation of diverse populations in clinical research

  2021cites this paper
• Characterizing plasma NfL in a community‐dwelling multi‐ethnic cohort: Results from the HABLE study

  2021cites this paper
• A Precision Medicine Approach to Treating Alzheimer’s Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials

  2021cites this paper
• The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics

  2021cites this paper
• Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study

  2020cites this paper
• Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome

  2020cites this paper
• Epigenetic Regulation in the pathophysiology of Lewy Body Dementia.

  2020cites this paper
• An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

  2020cites this paper
• Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome

  2020cites this paper
• Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study

  2019cites this paper
• Blood-Based Biomarkers for Alzheimer’s Disease and Related Dementias Potential two-step proteomic signature for Parkinson’s disease: Pilot analysis in the Harvard Biomarkers Study

  2019cites this paper
• Title : An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

  2019cites this paper
• CSF proteome pro fi ling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease

  year unknowninfluential citation